Jeffrey S. Weber, MD, PhD
Professor of Medicine
Deputy Director, Laura and Isaac Perlmutter Cancer Center
NYU School of Medicine
New York, NY
This 5-part educational activity will cover the treatment and management of patients with cancer who are on or considering immunotherapy, and will focus on aspects of care in this area such as mechanisms of cancer and targeted therapies, immune-related adverse events, investigational directions, and other immunotherapy-related treatment decisions.
This initiative is designed to meet the educational needs of community and academic medical oncologists, hematologists, allied health and advanced practitioners (NP, PA, PharmD), and other relevant healthcare professionals involved in immuno-oncology, precision medicine, and treatment decision-making in cancer.
Upon completion of the program, attendees should be able to:
- Discuss the pathophysiology of adult malignancies with a focus on tumor immunosurveillance and immune evasion
- Review significant advances and unmet medical needs associated with currently available immuno-oncology therapies including innate and adaptive resistance mechanisms (eg, T-cell exhaustion)
- Describe immune pathways that may be targeted to overcome immune-evasion mechanisms and emerging clinical data on novel immuno-oncology agents
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity is planned and produced in accordance with ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 0.25 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent for their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with cancer. CNE Credits: 0.25 ANCC Contact Hour(s).
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Weber has disclosed that he is a stockholder for Altor, Biond, and CytoMx. He is a consultant for AstraZeneca, Bristol-Myers Squibb, EMD Serono, Genentech, GlaxoSmithKline, Incyte, Merck, and Sellas Life Sciences.
CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Chris Drury, MA, MS, Medical Director for Med Learning Group has nothing to disclose.
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group has nothing to disclose.
Cathy Herbert, Medical Director for Med Learning Group, has nothing to disclose.
Melissa A Johnson, Sr. Program Manager of Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the enduring activity.
3. Submit the evaluation form to Med Learning Group.
You will receive your certificate as a downloadable file after the activity.
Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/
RELEASE DATE: May 13, 2019
EXPIRATION DATE: May 13, 2020
Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.